tbuckley/cabot-search huggingface dataset:
AB1461-HPR Frequency of rheumatoid factor isotypes in paraguayan patients with rheumatoid arthritis
Authors: L Roman, S. Riquelme-Granada, G. Avila-Pedreti, I. Acosta-Colman, M.E. Acosta, I. de Guillen, M. Duarte, M.T. Filartiga, S. Cabrera-Villalba
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid Arthritis is a chronic rheumatic disease characterised by polyarticular inflammation. The rheumatoid factor is one of the most known prognostic markers, not only its presence, but also the levels. It also presents different isotypes (IgG, IgM, IgA), which can affect the course of the disease. <h3>Objectives</h3> To analyse the presence of different rheumatoid factor (RF) isotypes in Paraguayan patients with rheumatoid arthritis (RA) and to study their association with clinical and analytical characteristics. <h3>Methods</h3> Descriptive, cross-sectional study. A large number of clinical and serological variables were recorded. The anti-CCP 3.1 and Rheumatoid factor (RF) isotypes IgA, IgG, and IgM were measured in serum samples by ELISA (enzyme-linked immunosorbent assay) (NV&lt;17 U/ml). Statistical analysis was performed using SPSS v.23. Quantitative variables were characterised by their means and standard deviations, while the qualitative variables were characterised according to the percentage of patients. The comparison of clinical and serological variables was performed using the chi-squared test and the student test respectively for qualitative and quantitative variables. <h3>Results</h3> 103 patients with RA were included, 86.4% were female, with a median age of onset of 44.7±13.6 years, and the mean disease duration was 7.13±7.03 years. The olygoarticular onset was the most frequent (46.6%). 13.7% were smokers. Extra-articular manifestations were present in 13.5%. The most frequent treatment was methotrexate (84.3%). Erosions were observed in 43.2% of patients. 28% were in remission of the disease measured by the DAS28 index. The average of HAQ was 0.47%±0.58. 91.3% had anti-CCP positive, the mean anti-CCP levels were 290.5±152.8 U/mL. RF isotypes was observed in 75.7%, 53.4% and 38.8% for IgM, IgA and IgG respectively. Mean levels were as follow, IgA 85.62±56.6 U/mL, IgM 96.7±30.9 U/mL, IgG 70.98±72.42 U/mL. 32% of the patients had 2 isotypes of RF, while 25.2% had the 3 isotypes. The 57.3% had ≥2 isotypes of RF. We did not find significant differences when comparing gender, age, disease duration, form of onset, extra-articular manifestations, smoking status, erosions, disease activity, HAQ, treatment, between the different RF isotypes, and levels, except in the presence of anti-CCP with the RF-IgM isotype (p&lt;0.000). <h3>Conclusions</h3> This is the first study of RF isotypes in Paraguayan patients with RA. The most frequent isotype of RF was IgM. More than 50% of patients had 2 or more RF isotypes. The majority of patients with positive RF had high levels of different isotypes, being the highest IgM. <h3>Disclosure of Interest</h3> None declared
SAT0077 Change in frequency of arthroplasty surgery in rheumatoid arthritis: a 13 year population health study
Authors: J.G. Hanly, L. Lethbridge, C. Skedgel
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Improvement in the medical management of rheumatoid arthritis (RA) over the past two decades may have reduced the need for arthroplasty surgery but the literature to date has reported inconsistent findings. <h3>Objectives</h3> To compare the annual frequency of hip, knee and other arthroplasty surgery in a prevalent cohort of RA cases and matched controls over 13 years. <h3>Methods</h3> A retrospective cohort study was performed utilising administrative healthcare data from approximately 1 million people with access to universal healthcare between 1997 and 2010. RA cases were identified using a previously validated RA case definition in the same dataset.<sup>1</sup> Each case was matched by age and sex to 4 randomly selected controls. The annual frequency of arthroplasties in cases and controls was compared. In addition the frequency of coronary artery interventions (bypass grafting, angioplasty and stenting) was compared. Data included physician billings, hospital discharges and patient registry information using ICD-9 and ICD-10. Statistical analysis used least squares regression t-tests and 2-proportion z-tests. <h3>Results</h3> The number (prevalence) of RA cases increased from 3913 (0.42%) to 4911 (0.52%) over the study. The mean (SD) age changed from 56.7 (15.9) to 60.1 (14.9) years and the proportion of females from 70.8% to 73.9%. In both the first and last years of the study the frequency of all arthroplasty procedures was higher in cases than controls (p&lt;0.001) (Table 1). Over time there was a gradual and significant reduction in arthroplasty surgery in RA cases by 51.9% (p&lt;0.001). This was in contrast to controls in whom the frequency of procedures increased by 31.9% (p=0.002) with the exception of hip arthroplasty. For the latter procedure, the frequency decreased by 63% in RA cases (p&lt;0.001) and 35% in controls (p=0.617). In contrast to arthroplasty procedures the frequency of cardiac procedures, which were higher in RA cases in both the first (p=0.013) and final (p=0.003) years of observation, increased in both cases and controls over time although did not reach statistical significance in either. <h3>Conclusions</h3> There was a striking reduction in arthroplasty surgery in RA cases over 13 years of observation. Lack of similar changes in controls and sustained rates of cardiac procedures over the same time suggests that this was not due to limited surgical access for RA patients. Improvement in medical treatment of RA is likely responsible. <h3>Reference</h3> [1] Hanly JG, Thompson K, Skedgel C. The use of administrative healthcare databases to identify patients with Rheumatoid Arthritis. Access Rheumatology: Research and Reviews 2015:7;69–75. <h3>Disclosure of Interest</h3> None declared
THU0460 Fully integrated 18f-fdg pet/mr in large vessel vasculitis
Authors: R. Padoan, F. Crimì, M. Felicetti, F. Padovano, L. Punzi, C. Lacognata, R. Stramare, D. Cecchin, F. Bui, P. Zucchetta, F. Schiavon
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Positron emission tomography (PET) is a non-invasive imaging method that detects <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake in vessel's walls. Its simultaneous combination with magnetic resonance (MR) would offer not only a more detailed morphological analysis of the vessels but also a reduction of the radiation, simplifying the clinical workflow and being logistically easier for the patient. <h3>Objectives</h3> To evaluate, for the first time up to now, the usefulness of a fully integrated 18F-FDG PET/MR in a series of large vessels vasculitides (LVV) patients. <h3>Methods</h3> We performed a controlled non-randomised prospective study. Images were acquired on a fully integrated PET/MR scanner (Siemens Biograph mMR), consisting in a complete MR protocol and FDG-PET whole body imaging. We evaluated vessel's standard uptake value (SUV) maximum and wall thickness (WT), defined as the mean of 4 measures (at 12, 3, 6 and 9 o'clock) at the inferior margin of D5, D9, D12, L3 and at thickest point (max WT). <h3>Results</h3> 23 LVV patients were included, 56.5% GCA, 34.8% TAK and 8.7% isolated aortitis, all Caucasian, mostly females (82%). We considered 55 PET scans, 32/55 in LVV group (from min. 1 to max. 3 scans/patient) mainly during follow-up (29/32 scans), and 23/55 in control group. Considering patients with abdominal aorta involvement, we found higher SUV max compared to controls, in all sites, regardless of disease activity. Mean WT resulted higher in patients than controls, but did not significantly differ between PET active or inactive patients (figure 1). Mean WT positively correlated with age in both cohorts, inversely correlated to disease duration in LVV patients, while no correlation with SUV max was observed. Despite clinical assessment was suggestive of remission in 24 (75%) cases before PET/MR acquisition, a normal uptake was present only in 12 (50%) of them. On the contrary, all patient with active disease at clinical examination (8, 25%) had also a positive PET/MR. Cohen's K coefficient between clinical assessment and imaging was poor (K Cohen=0, 33, 0.11–0.55). Finally, we found no significant correlation between SUV max and acute phase reactants. Demographic and clinical data of LVV patients. <h3>Conclusions</h3> PET/MR is a safe imaging technique capable of detecting vasculitic inflammation, similar to PET/CT, but with a greater anatomical definition. The low radiological exposure represents a valid alternative to PET/CT for disease monitoring, especially in young women. <h3>Disclosure of Interest</h3> None declared
Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types
Authors: Neeraj Y Saini, Rima M. Saliba, Gabriela Rondon, Farzaneh Maadani, Uday Popat, Betul Oran, Chitra Hosing, Qaiser Bashir, Amanda L. Olson, Yago Nieto, Amin M. Alousi, Partow Kebriaei, Samer A. Srour, Rohtesh S. Mehta, Paolo Anderlini, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Issa F. Khouri, Luis E. Fayad, Hun Ju Lee, Nathan H. Fowler, Simrit Parmar, Jason R. Westin, F. B. Hagemeister, Richard E Champlin, Stefan O. Ciurea
Journal: Blood (2018)
THU0595 Clinical and therapeutical differences between adults and children in a colombian cohort with inflammatory idiopatic myopathy
Authors: R. Fuentes, M. Cañola, J.C. Diaz-Coronado, A. Rojas-Villarraga, D. Hernandez-Parra, P. Perez-Estrada, J.C. Salazar-Uribe, R. Pineda-Tamayo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Age-related autoimmunity is a key differentiating factor with diverse presentations in different age groups possibly depending on immune regulatory mechanisms. Even patients with the same diagnostic category may have different presentations according to age and other factors. Inflammatory Idiopathic Myopathies (IIM) are not the exception with important clinical and prognostic differences between adults and children. <h3>Objectives</h3> To describe the clinical and therapeutical differences between adults and children (younger tahn 18 m years old) in a cohort with IIM <h3>Methods</h3> A cross-section retrospective research was done with data collected between 2014 and 2017 from a population diagnosed with IIM according to Peter and Bohan criteria and followed up for at least six months. Statistical association was evaluated by means of Chi-square and Fisher's tests. <h3>Results</h3> Out a total of 149 patients, 112 were adults and 37 were children. There was significant difference between the clinical presentation of symmetrical muscle weakness 98% in adults vs 73% in children (p: 0,0001), Gottron's papules 32% vs 89% (p: 0,0001), Heliotrope rash 31% vs 62% (p: 0,0016), Calcinosis cutis 1% vs 37% (p: 0,0001), Dermatological involvement 47% vs 94% (p: 0,0001), Myopathic changes in the electromyogram 41% vs 25% (p: 0,0001), and Myopathy proven biopsy 41% vs 25% (p: 0,0001). Theraepeutical options showed a significant difference in the use of steroid therapy 93% vs. 84% (p: 0,045), Methotrexate (58% vs 91% p: 0,0001), Azatioprine (62% vs 27% p: 0,0002) and Cloroquine (31% vs 73% p: 0,0001). Other therapies like Cyclophosphamide (19% vs 5% p: 0,04) and Inmunoglobulins (23% vs 5% p: 0,01) were significantly different between adults and children. EMG, electromyogram <h3>Conclusions</h3> Several differences in the clinical and therapeutical characeristics were found between adults and children with IIM. Adults had more frequently symmetrical weakness, myopathic changes in EMG and biopsy proven myopathy. In contrast children had higher skin involvement. Calcinosis constituded an important manifestation of IIM in children. These results suggest that paediatric IIM is a distinct sub-phenotype related to the early age at onset and possibly mediated by different immune interplay key factors. <h3>Reference</h3> [1] Tansley S, et al. Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes.1040–8711 Copyright!2015Wolters Kluwer Health, Inc <h3>Disclosure of Interest</h3> None declared
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
Authors: Mattia Boeri, Massimo Milione, Claudia Proto, Diego Signorelli, Giuseppe Lo Russo, Carlotta Galeone, Carla Verri, Mavis Mensah, Giovanni Centonze, Antonia Martinetti, Elisa Sottotetti, Ugo Pastorino, Marina Chiara Garassino, Gabriella Sozzi
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Immune-checkpoint inhibitors (ICI) have improved the survival of patients with non–small cell lung cancer (NSCLC). However, only a subset of patients benefit from ICIs, and the role of PD-L1 as predictive biomarker is still debated. A plasma immune-related miRNA-signature classifier (MSC) was established in lung cancer screening settings to identify the lethal form of the disease in early stages. In this exploratory study, we tested the efficacy of the MSC as prognostic marker in patients with advanced NSCLC treated with ICIs. Experimental Design: The MSC risk level was prospectively assessed in a consecutive series of 140 patients with NSCLC before starting treatment with ICIs. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in strata of PD-L1 and MSC alone or combined were considered as endpoints. Multiple plasma samples to monitor MSC risk level during treatment were also profiled. Results: Adequate tissue and plasma samples were available from 111 (79%) and 104 (75%) patients with NSCLC, respectively. MSC risk level was associated with ORR (P = 0.0009), PFS [multivariate HR = 0.31; 95% confidence interval (CI), 0.17–0.56; P = 0.0001], and OS (multivariate HR = 0.33; 95% CI, 0.18–0.59; P = 0.0002). The combination of MSC and PD-L1 stratified patients into three risk groups having 39%–18%–0% 1-year PFS (P &amp;lt; 0.0001) and 88%–44%–0% 1-year OS (P &amp;lt; 0.0001), according to the presence of 2–1–0 favorable markers. During treatment, MSC risk level decreased or remained low until tumor progression in patients with responsive or stable disease. Conclusions: The plasma MSC test could supplement PD-L1 tumor expression to identify a subgroup of patients with advanced lung cancer with worse ORR, PFS, and OS in immunotherapy regimens.
C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells
Authors: Izabela Aparecida Lopes, Miroslava Kardosova, Thiago Mantello Bianco, Adriana Queiroz Arantes, Cleide Araújo Silva, Priscila Santos Scheucher, Daniel G. Tenen, Sanghoon Lee, Eduardo Magalhães Rego, Robert S. Welner, Meritxell Alberich-Jorda, Lorena Lobo Figueiredo-Pontes
Journal: Blood (2018)
Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): Final results.
Authors: Sarmad Sadeghi, David I. Quinn, Denice D Tsao-Wei, Omid Hamid, James Hu, Anne K. Schuckman, Siamak Daneshmand, Susan G. Groshen, Derek Raghavan, Tanya B. Dorff
Journal: Journal of Clinical Oncology (2013)

4531 Background: Modern therapy (Tx) for GCC has transformed the disease but challenges remain in managing rGCT. Methods: 30 men with GCC progression ≤4 weeks after a standard (7), salvage (17), or stem cell (6) regimen were enrolled in the trial. PS&lt;=2, Age&gt;16, PD by RECIST/markers (Tm) criteria. Growing teratoma syndrome excluded. Regimen: paclitaxel 170mg/m 2 /3h; gemcitabine 800mg/m 2 /80min; oxaliplatin 100mg/m 2 /90min, increased to 125mg/m 2 in cycle 2 if no major toxicity. Mg 2+ and Ca 2+ infused before oxaliplatin. The regimen was designed to maximize Oxaliplatin density with full dosing of pts with recovering marrow and dose escalation for pts with limited toxicity in cycle 1. Retreatment if ANC ≥1000 or 700 with monocytosis, platelets &gt;75K. Pts with normalized Tm had 3 further cycles. Primary endpoint: Response (RR); 2nd: OS, PFS, toxicity. Results: Median GOT cycles 6 [1-14].Dose escalation in 9 pts correlated with improved OS (p=0.03). Tm normalized in 23.3%. 5 pts (4 PR, 1 SD) became NED after definitive surgery. No link between ethnicity and RR or OS. Conclusions: 2-weekly GOT for rGCC produced high rates of Tm and RECIST response and rendered 5 pts resectable. Dose escalation was associated with better OS and will be explored with GCSF in a trial extension. The median OS of 18.3 mos compares favorably with 6-13.5 mos in other series (Oechsle K Eur Urol 60: 850, 2011). Clinical trial information: NCT00183820. [Table: see text]
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Authors: M.V. Dieci, P. Conte, G. Bisagni, A.A. Brandes, A. Frassoldati, L. Cavanna, A. Musolino, F. Giotta, A. Rimanti, O. Garrone, E. Bertone, K. Cagossi, S. Sarti, A. Ferro, F. Piacentini, A. Maiorana, E. Orvieto, M. Sanders, F. Miglietta, S. Balduzzi, R. D’Amico, V. Guarneri
Journal: Annals of Oncology (2019)

BackgroundThere is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm.Patients and methodsStromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan–Meier curves were estimated for patients with TILs ≥20% and TILs <20%. Median follow-up was 6.1 years.ResultsMedian TILs was 5% (Q1–Q3 1%–15%). Increased TILs were independently associated with better DDFS in multivariable model [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59–0.89, P = 0.006, for each 10% TILs increment]. Five years DDFS rates were 91.1% for patients with TILs <20% and 95.7% for patients with TILs ≥20% (P = 0.025). The association between 10% TILs increments and DDFS was significant for patients randomized to 9 weeks of trastuzumab (HR 0.60, 95% CI 0.41–0.88) but not for patients treated with 1 year of trastuzumab (HR 0.89, 95% CI 0.71–1.12; test for interaction P = 0.088). For patients with TILs <20%, the HR for the comparison between the short versus the long arm was 1.75 (95% CI 1.09–2.80, P=0.021); whereas, for patients with TILs ≥20% the HR for the comparison of short versus long arm was 0.23 (95% CI 0.05–1.09, P = 0.064), resulting in a significant interaction (P = 0.015).ConclusionsTILs are an independent prognostic factor for HER2-positive early breast cancer patients treated with adjuvant chemotherapy and trastuzumab and may refine the ability to identify patients at low risk of relapse eligible for de-escalated adjuvant therapy.
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Authors: Maurice Beghetti, Richard N. Channick, Kelly M. Chin, Lilla Di Scala, Sean Gaine, Hossein‐Ardeschir Ghofrani, Marius M. Hoeper, Irene M. Lang, Vallerie V. McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simonneau, Olivier Sitbon, Victor F. Tapson, Nazzareno Galiè
Journal: European Journal of Heart Failure (2019)

Aims Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a poor prognosis compared with other CHD‐PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with corrected CHD‐PAH from randomised controlled trials is limited. The purpose of these analyses was to characterise the corrected CHD‐PAH patients from the GRIPHON study and examine the response to selexipag. Methods and results Out of the 110 patients diagnosed with corrected CHD‐PAH, 55 had atrial septal defects, 38 had ventricular septal defects, 14 had persistent ducti arteriosus, and 3 had defects not further specified. Hazard ratios (HR) and 95% confidence intervals (CI) for the primary composite endpoint were calculated using Cox proportional hazard models. Compared with the non‐CHD patients from GRIPHON, patients with corrected CHD‐PAH were slightly younger, with a greater proportion being treatment‐naive and in World Health Organization functional class I/II. The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD‐PAH who were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most common adverse events were those known to be related to selexipag. Conclusions These post‐hoc analyses of GRIPHON provide valuable information about a large population of patients with corrected CHD‐PAH, and suggest that selexipag may delay disease progression and was well‐tolerated in patients with corrected CHD‐PAH.
PARE0011 Funka utan skam to function without shame
Authors: T. Diao
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Introduction: Kids, youngsters and adults with an immigrant background are more vulnerable in the new country of arrival. It is quite hard to learn a new language and the rules and regulation in the new country. In several cultures, people with a visible or invisible disability can experience guilt and Shame because of their diagnoses. Due to the cultural background, most of the time the families are also feeling the same. This feeling could be conscious or unconscious due to the cultural background. Therefor did the Swedish National Assyrian Organization (SNAO) take the initiative to start a knowledge-sharing project together with the Swedish Rheumatism Association and the Swedish Neuro-Association to inform and educate the kids and their parents with the Assyrian background. <h3>Objectives</h3> The aim of this project is to empower the persons and families suffering of an RMD or/and neurological disease among the immigrants from Syria and to break barriers within the immigran's society as well as saving on the national welfare system. <h3>Results</h3> To achieve such a project the SNAO applied for funds from the Swedish General Inheritance fund nad worked closely with the Swedish Rheumatism Association as well as the Swedish Neuro-Association. The project included other stakeholders that could embrace the goal and use unconventional methods to mark the point and reach out to the target group. Organizing weekend seminars open for to the target group Working with <i>Läsa för integration</i> (Reading for integration) http://www.lasaforintegration.se/index.html Opratat is a theater group that lifts difficult subjects to the surface and make a pedagogic scen of the subject. http://anhoriga.se/opratat/ The Swedish Disability Rights Federation: that enable the project to reach a broader target but also to reach the decision makers. <h3>References</h3> The project reach a great number of immigrant with an Assyrian background and could inform the attendees about their right and how the Swedish society works. This was of a great help to the families as well as the kids. <h3>Disclosure of Interest</h3> None declared
Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency
Authors: Sonia García-Gómez, Rebeca Chaparro, Amin Safa, Ana Van Den Rym, Rubén Martinez-Barricarte, Lazaro Lorenzo, Silvia Sánchez-Ramón, Victor Toledano, Carolina Cubillos-Zapata, Eduardo López-Collazo, Maria Dolores Martín-Arranz, Eduardo Martín-Arranz, Maria Vela, Pablo Gonzalez-Navarro, Antonio Pérez-Martínez, Jean-Laurent Casanova, Maria José Recio, Rebeca Pérez de Diego
Journal: Journal of Allergy and Clinical Immunology (2019)